Articles From: Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients to MEDIA ADVISORY - Keurig Green Mountain, Inc. MINI Plus Brewer Statement


Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today positive initial Phase 2 data with revusiran (ALN-TTRsc), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR cardiac amyloidosis.
Sign-up for Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world’s leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia.
Sign-up for Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today it has initiated the ENDEAVOUR Phase 3 clinical trial of revusiran in transthyretin (TTR)-mediated familial amyloidotic cardiomyopathy (FAC). FAC is one of the predominant clinical manifestations of TTR-mediated amyloidosis (ATTR), and afflicts an estimated 40,000 people worldwide.
Sign-up for Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks
Alnylam Pharmaceuticals, Inc .
Sign-up for Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has completed enrollment in its Phase 2 clinical trial with revusiran (re-VOO-si-ran), the recommended International Nonproprietary Name (INN) for ALN-TTRsc.
Sign-up for Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the appointment of Pushkal Garg, M.D., to the position of Senior Vice President, Clinical Development.
Sign-up for Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development investment picks
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline.
Sign-up for Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases.
Sign-up for Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq: MDCO), a global biopharmaceutical company focused on hospital care, announced today that Alnylam has initiated a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia.
Sign-up for Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today its pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease.
Sign-up for Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or “STArs” investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of a peer-reviewed article in the Journal of the American Chemical Society describing the discovery of GalNAc-conjugated siRNA as a novel strategy for delivery of RNAi therapeutics.
Sign-up for New Paper in Journal of the American Chemical Society Documents Pioneering Discovery of GalNAc-Conjugated siRNA by Alnylam Scientists investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines.
Sign-up for Alnylam Launches “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Swedish Medical Products Agency (MPA) to initiate a Phase 1 clinical trial with ALN-AS1, a subcutaneously administered investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS-1) for the treatment of hepatic porphyrias, including acute intermittent porphyria (AIP). Per the filed CTA, the Phase 1 trial of ALN-AS1 will be performed first in AIP patients who are asymptomatic “high excreters” (ASHE) – patients with a mutation in the porphobilinogen deaminase (PBGD) gene and elevated urinary aminolevulinic acid (ALA) and porphobilinogen (PBG) levels, but no recent symptoms of a porphyria attack – and then in AIP patients who experience recurrent porphyria attacks.
Sign-up for Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the election of Michael W.
Sign-up for Alnylam Elects Michael W. Bonney to Its Board of Directors investment picks
2015/1/15
Booking.com Launches Booking Now, the First Truly Global App for Spontaneous Bookers Canada NewsWire More Than 580,000 Accommodations Ready to Book in Just Two Taps Personalized Search Results with Booking.com's Best Price Guarantee AMSTERDAM , Jan.
Sign-up for Booking.com Launches Booking Now, the First Truly Global App for Spontaneous Bookers investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982831001&sourceType=1 http://media3.marketwire.com/logos/20120223-PROPH.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Prophecy Provides Background on Pulacayo Property and Commences Evaluation of Historic Tailings investment picks
NEW YORK, Dec.
Sign-up for Varonis Helps Ipswich Hospital Prevent a Data Haemorrhage investment picks
2014/12/21
Electrical Distributor Deploys NetSuite OneWorld to Improve Efficiencies Across Four Businesses in Thailand BANGKOK , Dec.
Sign-up for NetSuite OneWorld to Power Compomax's Rapid Expansion Plans in Thailand investment picks
Integrated Device Technology, Inc. ( IDT ® ) (NASDAQ:IDTI) today expanded its VersaClock ® 5 family of low-power field-programmable clock generators with six new products that deliver industry-leading capabilities in multiple configurations to match varying application types.
Sign-up for IDT Expands VersaClock 5 Family with Six New Products, Delivering Best-in-Class Jitter Performance in Cost-Effective Configurations investment picks
FORT WASHINGTON, Pa., Dec.
Sign-up for Vitae Pharmaceuticals Among 2014 Best Places to Work in PA investment picks
2015/1/2
By Daniel Gilbert Linn Energy LLC and Breitburn Energy Partners LP , the two largest U.S. energy producers by revenue operating as partnerships, slashed shareholder payouts and capital spending in moves that could pressure rivals to take similar steps.
Sign-up for Linn, Breitburn Slash Dividends; Cuts Capital Budgets--3rd Update investment picks
2015/1/14
No matter how you prefer your cup of coffee, there’s no denying the single-serve brewing trend is piping-hot.
Sign-up for GE Appliances and Keurig® Brew Up the Next Big Thing in Refrigeration investment picks
2015/1/20
In a recent survey office workers say coffee plays an important part in success in the workplace.
Sign-up for New Survey: 89% of Office Workers Say a Good Cup of Coffee Can Make Entire Workday Better investment picks
Keurig Green Mountain, Inc., (Keurig) (NASDAQ: GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, today announces that it is now the exclusive manufacturer of Meijer Brand K-Cup ® packs for the Keurig ® hot brewing system.
Sign-up for Keurig Green Mountain Welcomes Meijer K-Cup Packs into the Keurig Brewed Family investment picks
Keurig Green Mountain, Inc., (Keurig) (NASDAQ: GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, today announced that Frances G.
Sign-up for Keurig Green Mountain Announces that Frances G. Rathke, Chief Financial Officer and Treasurer, will leave the Company in Fiscal Year 2015 investment picks
Keurig Green Mountain, Inc. (Keurig) (NASDAQ: GMCR) and Caribou Coffee announced that the companies have renewed their partnership with a 10-year agreement for the manufacturing, marketing, distribution, and sale of Caribou Coffee in Keurig ® pack formats for Keurig ® consumer and commercial hot brewing systems.
Sign-up for Keurig Green Mountain and Caribou Coffee Announce Expanded Agreement investment picks
Keurig Green Mountain, Inc. (Keurig) (NASDAQ:GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, and Community Coffee Company, the largest family owned and operated retail coffee brand in America, announced a multi-year licensing, manufacturing, and distribution agreement to bring Community ® coffee to Keurig ® portion pack formats for consumer and commercial Keurig ® hot brewing systems.
Sign-up for Keurig Green Mountain and Community Coffee Company Announce Partnership investment picks
MTY Food Group, Inc. (MTY) (TSX: MTY), franchisor and operator of multiple concepts of quick service restaurants, and Keurig Canada Inc., a subsidiary of Keurig Green Mountain, Inc. (Keurig) (NASDAQ: GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, today announced the companies have reached an agreement regarding the Van Houtte Café-Bistros franchise network.
Sign-up for MTY Food Group and Keurig Canada Announce Agreement Taking Van Houtte-Branded Café-Bistros into New Era investment picks
Keurig Green Mountain, Inc. (Keurig) (NASDAQ: GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, today announced its business results for the 13 weeks and 52 weeks ended September 27, 2014.
Sign-up for Keurig Green Mountain Announces Strong Fourth Quarter and Fiscal Year 2014 Financial Results investment picks
After receiving reports of hot liquid escaping from MINI Plus Brewing System units during use, Keurig Green Mountain, Inc. (Keurig) contacted the U.S. Consumer Product Safety Commission (CPSC) and Health Canada to begin the process for a voluntary recall.
Sign-up for MEDIA ADVISORY - Keurig Green Mountain, Inc. MINI Plus Brewer Statement investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients to MEDIA ADVISORY - Keurig Green Mountain, Inc. MINI Plus Brewer Statement
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent